Background {#Sec1}
==========

Lung cancer is known to be the leading cause of cancer-related mortality among the men and women around the world. It has reported that small cell lung cancer (NSCLC) is responsible for the 85 % of lung cancer and the five-year survival rate for lung cancer is only 15 % \[[@CR1]\].

Surgical resection is well known as the main treatment method for patients with NSCLC to date, but most patients are metastatic or locally advanced when NSCLC is diagnosed that rules out curative resection. In these situations, conventional cytotoxic chemotherapy is an available strategy for treatment, but with a 5-year survival rate of only 13 % \[[@CR2], [@CR3]\]. Therefor, discovery of new specific therapeutic targets may provide effective management of disease.

MicroRNAs (miRNAs) are small non-coding RNA molecules, which can play a significant role in the regulation of human gene expression via directing their target mRNAs for degradation or translational repression. Several studies have reported that various miRNAs can be involved in many biological functions including cellular proliferation, differentiation, and apoptosis \[[@CR4]\]. It is worth noting that correlation of miRNA expressions with tumor prognosis have been previously reported \[[@CR5], [@CR6]\]. Moreover, previous studies indicated that miRNAs act as oncogenes or tumor suppressors in human carcinogenesis. Dysregulation of microRNA expression may play a key role in tumorigenesis and cancer progression \[[@CR7]--[@CR9]\]. The role of microRNAs as potential therapeutic targets was previously investigated in various types of cancers \[[@CR10]\]. Previous studies indicated that MiRNA-148b (miR-148b) was down-regulated in many kind of cancer such as colon, oral, pancreatic, gastric, and small cell lung cancer \[[@CR11]--[@CR13]\]. Ge et al. (2015) have found that low expression of miR-148b in NSCLC tissues has prognostic value \[[@CR13]\]. On the other hand, functional studies indicated that miR-148b can function as a tumor-suppressive RNA by targeting specific oncogenes \[[@CR12], [@CR14]\].

Azizi et al. (2014) reported that miR-148b can reactivate tumor suppressor genes via suppression of DNA methyltransferase-1 gene in pancreatic cancer cell lines \[[@CR15]\]. Moreover, Liu et al. (2014) have indicated that miR-148b expression is low in NSCLC cells by targeting carcinoembryonic antigen (CEA) \[[@CR12]\]. Therefore, Understanding the molecular mechanism of cancer development and progression may be beneficial to identify the therapeutic effects of these mechanisms.

In the present study, we used Real-time PCR to quantify the expression level of miR-148b in 104 NSCLC cancers. Furthermore, we investigated to clarify the relationship of miR-148b with clinicopathological features and survival in patients with NSCLC.

Methods {#Sec2}
=======

Clinical specimens {#Sec3}
------------------

A total of 104 NSCLC patients were diagnosed in this study also cancer tissues and adjacent normal tissues were evaluated after taking the informed consents. All patients underwent surgical resection at Tehran and Mashhad between March 2009 and March 2014. It is worth mentioning that the patients were not previously treated with chemo or radio-therapy before operation. Clinical information of NSCLC patients were summarized in Table [1](#Tab1){ref-type="table"}.Table 1Correlation between miR-148b expression and clinicopathological features of patients with NSCLCmiR-148b expressionClinicopathological CharacteristicsCases (n)LowHigh*P* valueSex Male5825330.51 Female462125Age (years) \<504018220.24 ≥50643034TNM stage I /II5822360.001 III /IV463214Lymph node metastasis Yes4131100.023 No631647Histological type Adenocarcinoma4921280.65 Squamous cell carcinoma411823 Others1486Distant metastasis0.56 Yes1385 No915648

Quantitative Real-time PCR {#Sec4}
--------------------------

Total RNA and enrichment of small RNA was isolated from fresh samples using the miRVana™ microRNA. Isolation Kit (Applied Biosystems/Ambion, Austin, TX, USA) according to the manufacturer's protocol. Moreover, we used TRIzol reagent (Invitrogen, Carlsbad, California, USA) to extracted total RNA from fresh cultured cells.

Real-time PCR was carried out using an Express SYBR® Green ER qPCRs supermix Universal kit (Invitrogen) by system of Rotor-gene 6000 (Qiagen). The relative amount of miR-148b was normalized with respect to U6 RNA. In current study, we used ^Δ^Ct method to calculate changes in expression. Moreover, 2ΔΔCt method was used to calculate the fold-change between cancer and normal tissue, that ^ΔΔ^Ct = ^Δ^Ct (target-reference in tumor samples) - ^Δ^Ct (target-reference in normal samples). The miRNAs expression levels in cancer compared to non-tumorous controls that were also calculated using 2^-ΔΔ^Ct method \[[@CR14]\].

Statistical analysis {#Sec5}
--------------------

Statistical analysis was performed using the SPSS software 16.0 (SPSS Inc., Chicago, IL, USA). The differences between two groups were assessed using Student's t-test. Moreover, the chi-square test and Fisher's exact test were used to evaluate the relationships between miR-148b expression level and the clinicopathological characteristics. Differences were considered to be statistically significant at *P* \< 0.05. Differences in survival between two groups were analyzed using the log-rank test and Kaplan-Meier method. Furthermore, independent prognostic factors associated with patient survival were evaluated by multivariate Cox regression analyses.

Written informed consent was obtained from all participants. An approval of ethics committee by the Ethics Committee of the First Affiliated Hospital of Tehran and Mashhad was obtained. It was conducted in accordance with the guidelines of the Helsinki Declaration.

Results {#Sec6}
=======

The miR-148b expression in human NSCLC tissues and adjacent normal tissues {#Sec7}
--------------------------------------------------------------------------

Quantitative real-time PCR analysis showed that miR-148b was downregulated in tumor tissues when compared with corresponding adjacent normal lung tissues (0.34 ± 0.13 vs. 1.00 ± 0.57, *P* \< 0.05).

According to the median level of miR-148b, NSCLC patients were divided in to low and high expression groups. 55 cases were assigned to the low miR-14-8b expression group, while 49 cases were assigned to the high expression group.

The relationship between miR-148b expression level and clinicopathological features {#Sec8}
-----------------------------------------------------------------------------------

Results showed that decreased expression of miR-148b was significantly related to TNM stage (*P* = 0.001) and lymph node-metastasis (*P* = 0.023).

Nevertheless, miR-148b expression was not associated with other clinicopathological characteristics such as sex (*P* = 0.51), age (*P* = 0.24), histological type (*P* = 0.65), distant metastasis (*P* = 0.56), (Table [1](#Tab1){ref-type="table"}).

Survival analysis between low-expression group and high-expression group {#Sec9}
------------------------------------------------------------------------

Kaplan-Meier survival analysis and log-rank test suggested that low-expression group had significantly shorter overall survival (67.7 %) than high-expression group (32.3 %), (log-rank test *P* = 0.031; Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Correlation of miR-148b expression with survival time in NSCLC patients. Low-expression group of patients had significantly shorter overall survival than high-expression group (log-rank test; *P* = 0.031)

Multivariate Cox proportional hazards model for survival analysis {#Sec10}
-----------------------------------------------------------------

Multivariate Cox proportional hazards model analysis used to find whether miR-148b expression level and different clinicopathological features were independent prognostic markers for patients with NSCLC (Table [2](#Tab2){ref-type="table"}).Table 2Multivariate analysis with a Cox proportional hazards model between clinicopathological factors by Cox regression modelClinicopathological characteristicsHR95 % CI*P*-valueSex0.7410.412- 3.1340.573Age1.6310.845-3.1200.614TNM stage2.3821.525-9.1390.011Lymph node metastasis2.1240.972-6.6430.021Histological type0.4170.622-2.4240.423Distant metastasis1.6310.764-2.3750.551miR-148b level3.2151.543-10.6210.021

The result indicated that low miR-148b expression was independently linked to poor survival of patients with NSCLC (HR = 3.215, 95 % CI: 1.543-10.621, *P* = 0.021) and other factors were not significant independent predictor of survival in NSCLC patients (Table [2](#Tab2){ref-type="table"}).

Discussion {#Sec11}
==========

It can be helpful to realize the underlining molecular mechanisms and to identify powerful prognostic indicator for NSCLC. Several studies have been found significant correlation of miRNA expressions with tumor prognosis \[[@CR5], [@CR16]\]. For instance, ectopical expression of miR-148b inhibits the invasion in breast cancer cells and also metastasis to lung from breast cancer cells. It has been indicated that miR-148b has potential function for limiting of breast cancer development \[[@CR16]\]. In the current study, we evaluated the expression of miR-148b in NSCLC cancers. Quantitative real-time PCR analysis showed that miR-148b was downregulated in tumor tissues when compared with corresponding adjacent normal lung tissues. We then investigated the relationship of miR-148b expression with clinicopathological features and survival in patients with NSCLC. Our finding suggested that low expression of miR-148b was significantly related to TNM stage and lymph node-metastasis. This result suggested that reduced expression of miR-148b may be responsible for the progression of NSCLC.

Ge et al. (2015) suggested that the level of miR-148b was downregulated in NSCLC patients, and correlated with tumor stage \[[@CR13]\].

Liu et al. (2014) have indicated that miR-148b expression was decreased in NSCLC cells by targeting carcinoembryonic antigen (CEA), which results in CEA overexpression and disease progression in NSCLC \[[@CR12]\]. Song et al. (2011) have suggested that miR-148b targets CCKBR and suppresses gastric cancer cell growth \[[@CR14]\]. These findings provide that miR-148b was down-regulated in gastric cancer and play its role as a tumor suppressor via inhibiting cell proliferation.

Zhang et al. (2014) have found reduced expression of the MicroRNA-148b in human hepatocellular carcinoma (HCC) \[[@CR17]\]. It has been reported that the development of drug-resistant NSCLC cells is correlated with the deregulation of miR-148b expression. Moreover, expression level of miR-148b is contradictory associated with DNMT1 expression in the A549/DDP cells \[[@CR18]\].

In current study, Kaplan-Meier survival analysis and log-rank test suggested that low-expression group had significantly shorter overall than high-expression group of NSCLC patients.

Multivariate analysis with a Cox proportional hazards model between prognosis factors indicated that low miR-148b expression was independently linked to poor survival of patients with NSCLC, suggesting that miR-148b can serve as an independent prognostic factor of overall survival for patients with NSCLC. This findings are in agreement with previously published study demonstrating miR-148b expression was independently associated with overall survival of patients with NSCLC \[[@CR13]\].

Other studies have indicated that decreased expression of miR-148b was linked to poor overall survival of patients with hepatocellular, ovarian, breast and pancreatic carcinomas, NSCLC, and colorectal \[[@CR19]--[@CR24]\]. They reported that miR-148b serve as an independent prognostic factor marker in clinical practice.

Conclusions {#Sec12}
===========

In conclusion, this study demonstrated that miR-148b may play an important role as independent prognostic factor and/or biomarker for the prediction of survival in NSCLC. Moreover, our data recommend that miR-148b may serve as a new therapeutic target for NSCLC.
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